Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2011 Dec 23;5:16–32. doi: 10.1016/j.provac.2011.10.002

Non-animal replacement methods for human vaccine potency testing: state of the science and future directions

Richard McFarland a, Daniela Verthelyi b, Warren Casey c,⁎, Juan Arciniega a, Richard Isbrucker d, Michael Schmitt a, Theresa Finn a, Johan Descamps e, Yoshinobu Horiuchi f, Dorothea Sesardic g, Paul Stickings g, Nelson W Johnson h, Elizabeth Lipscomb h, David Allen h
PMCID: PMC7129268  PMID: 32288913

Abstract

NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods, and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. This report addresses methods and strategies identified by workshop participants for replacement of animals used for potency testing of human vaccines. Vaccines considered to have the highest priority for future efforts were (1) vaccines for which antigen quantification methods are already developed but not validated, (2) vaccines/components that require the largest number of animals, (3) vaccines that require an in vivo challenge test, and (4) vaccines with in vivo tests that are highly variable and cause a significant number of invalid tests. Vaccine potency tests identified as the highest priorities for replacement were those for diphtheria and tetanus, pertussis (whole cell and acellular), rabies, anthrax, polio vaccine (inactivated) and complex combination vaccines based on DT or DTwP/aP. Research into understanding the precise mechanism of protection afforded by vaccines and the identification of clinically relevant immunological markers are needed to facilitate the successful implementation of in vitro testing alternatives. This report also identifies several priority human vaccines and associated research objectives that are necessary to successfully implement in vitro vaccine potency testing alternatives.

Keywords: human vaccines, vaccine potency testing, vaccine safety testing, replacement alternatives, ICCVAM

References

  • 1.Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). The NICEATM-ICCVAM five-year plan (2008-2012): a plan to advance alternative test methods of high scientific quality to protect and advance the health of people, animals, and the environment. National Institute of Environmental Health Sciences, 2008. NIH Publication No. 08-6410. http://iccvam.niehs.nih.gov/docs/5yearplan.htm.
  • 2.Stokes W.S., Kulpa-Eddy J., McFarland R.M. Introduction and summary of the international workshop on alternative methods to reduce, refine, and replace the use of animals in vaccine potency and safety testing: state of the science and future directions. Proc Vaccinol. 2011;5:1–15. [Google Scholar]
  • 3.McFarland R., Verthelyi D., Casey W., Arciniega J., Isbrucker R., Schmitt M., Finn T., Descamps J., Horiuchi Y., Sesardic D., Stickings P., Johnson N.W., Lipscomb E., Allen D. Non-animal replacement methods for human vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol. 2011;5:16–32. doi: 10.1016/j.provac.2011.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kulpa-Eddy J., Srinivas G., Halder M., Hill R., Brown K., Roth J., Draayer H., Galvin J., Claassen I., Gifford G., WoodlandR, Doelling V., Jones B., Stokes W.S. Non-animal replacement methods for veterinary vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol. 2011;5:60–83. doi: 10.1016/j.provac.2011.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Casey W., Schmitt M., McFarland R., Isbrucker R., Levis R., Arciniega J., Descamps J., Finn T., Hendriksen C., Horiuchi Y., Keller J., Kojima H., Sesardic D., Stickings P., Johnson N.W., Lipscomb E., Allen D. Improving animal welfare and reducing and refining animal use for human vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol. 2011;5:33–46. doi: 10.1016/j.provac.2011.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Stokes W.S., Brown K., Kulpa-Eddy J., Srinivas G., Halder M., Draayer H., Galvin J., Claassen I., Gifford G., Woodland R., Doelling V., Jones B. Improving animal welfare and reducing animal use for veterinary vaccine potency testing: state-of-the-science and future directions. Proc Vaccinol. 2011;5:84–105. doi: 10.1016/j.provac.2011.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Isbrucker R., Levis R., Casey W., McFarland R., Schmitt M., Arciniega J., Descamps J., Finn T., Hendriksen C., Horiuchi Y., Keller J., Kojima H., Sesardic D., Stickings P., Johnson N.W., Allen D. Alternative methods and strategies to reduce, refine, and replace animal use for human vaccine post-licensing safety testing: state of the science and future directions. Proc Vaccinol. 2011;5:47–59. doi: 10.1016/j.provac.2011.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kulpa-Eddy J., Srinivas G., Halder M., Hill R., Brown K., Draayer H., Galvin J., Claassen I., Gifford G., Woodland R., Doelling V., Jones B., Stokes W.S. Alternative methods and strategies to reduce, refine, and replace animal use for veterinary vaccine post-licensing safety testing: state of the science and future directions. Proc Vaccinol. 2011;5:106–119. doi: 10.1016/j.provac.2011.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Roth J. Veterinary vaccines and their importance to animal health and public health. Proc Vaccinol. 2011;5:127–136. doi: 10.1016/j.provac.2011.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Schuchat A. Human vaccines and their importance to public health. Proc Vaccinol. 2011;5:120–126. doi: 10.1016/j.provac.2011.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Finn T. U. S. FDA Requirements for human vaccine safety and potency testing. Proc Vaccinol. 2011;5:137–140. doi: 10.1016/j.provac.2011.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hill R.E. USDA requirements for veterinary vaccine safety and potency testing. Proc Vaccinol. 2011;5:141–145. [Google Scholar]
  • 13.Isbrucker R., Sontakke S., Smith D. Health Canada's human vaccine lot release program: impact on the 3Rs. Proc Vaccinol. 2011;5:147–150. [Google Scholar]
  • 14.Woodland R. European regulatory requirements for veterinary vaccine safety and potency testing and recent progress toward reducing animal use. Proc Vaccinol. 2011;5:151–155. [Google Scholar]
  • 15.Horiuchi Y., Ochiai M., Kataoka M., Yamamoto A., Yuen C.-T., Asokanathan C., Corbel M., Kurata T., Xing D. Strategic approaches for developing alternative tests for safety and potency of vaccines. Proc Vaccinol. 2011;5:156–163. [Google Scholar]
  • 16.Shin J., Lei D., Conrad C., Knezevic I., Wood D. International Regulatory Requirements for Vaccine Safety and Potency Testing: A WHO perspective. Proc Vaccinol. 2011;5:164–170. [Google Scholar]
  • 17.Draayer H. Overview of currently approved veterinary vaccine potency testing methods and methods in development that do not require animal use. Proc Vaccinol. 2011;5:171–174. [Google Scholar]
  • 18.Claassen I. Case study of development, validation, and acceptance of a non-animal method for assessing veterinary vaccine potency. Proc Vaccinol. 2011;5:175–183. [Google Scholar]
  • 19.Levis R. Overview of the current status of human vaccine potency testing methods that replace animals. Presented at: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and Future Directions. NICEAM. Bethesda, MD. September 2010. Available at: http://iccvam.niehs.nih.gov/meetings/BiologicsWksp-2010/BiologicsWksp-present.htm.
  • 20.Descamps J. A Case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency. Proc Vaccinol. 2011;5:184–191. [Google Scholar]
  • 21.Keller J.E. Overview of currently approved serological methods with a focus on diphtheria and tetanus toxoid potency testing. Proc Vaccinol. 2011;5:192–199. [Google Scholar]
  • 22.Srinivas G. Refinement alternatives for veterinary vaccine potency testing: overview of currently approved serological methods. Presented at: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and Future Directions. NICEAM. Bethesda, MD. September 2010. Available at: http://iccvam.niehs.nih.gov/meetings/BiologicsWksp-2010/BiologicsWksp-present.htm.
  • 23.Stickings P., Rigsby P., Coombes L., Hockley J., Tierney R., Sesardic D. Animal refinement and reduction: alternative approaches for potency testing of diphtheria and tetanus vaccines. Proc Vaccinol. 2011;5:200–212. [Google Scholar]
  • 24.Arciniega J.L., Domínguez-Castillo R.I. Development and validation of serological methods for human vaccine potency testing: case study of an anthrax vaccine. Proc Vaccinol. 2011;5:213–220. [Google Scholar]
  • 25.Hendriksen C.F.M. Humane endpoints in vaccine potency testing. Proc Vaccinol. 2011;5:221–226. [Google Scholar]
  • 26.Kulpa-Eddy J., Srinivas G. Approaches to reducing animal numbers in vaccine potency testing. Proc Vaccinol. 2011;5:227–231. doi: 10.1016/j.provac.2011.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kulpa-Eddy J., Dusek D. Application of the consistency approach in the United States to reduce animal use in vaccine potency testing. Proc Vaccinol. 2011;5:232–235. [Google Scholar]
  • 28.Gifford G., Agrawal P., Hutchings D., Yarosh O. Veterinary vaccine post-licensing safety testing: overview of current regulatory requirements and accepted alternatives. Proc Vaccinol. 2011;5:236–247. [Google Scholar]
  • 29.Arciniega J.L., Corvette L., Hsu H., Lynn F., Romani T., Dobbelaer R. Target alternative vaccine safety testing strategies for Pertussis toxin. Proc Vaccinol. 2011;5:248–260. [Google Scholar]
  • 30.Rubin S.A. Toward replacement of the monkey neurovirulence test in vaccine safety testing. Proc Vaccinol. 2011;5:261–265. [Google Scholar]
  • 31.Zhou F.S.J., Messonnier M.L., Yusuf H.R., Shefer A., Chu S.Y., Rodewald L., Harpaz R. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005;159(12):1136–1144. doi: 10.1001/archpedi.159.12.1136. [DOI] [PubMed] [Google Scholar]
  • 32.Public Health Service Act. 1944 (as amended). 42 U.S.C. 6A. Available at: http://www.FDA.gov/RegulatoryInformation/Legislation/ucm148717.htm.
  • 33.Federal Food, Drug, and Cosmetic Act. 1938 (as amended). 21 U.S.C. 301 et seq. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm.
  • 34.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 21, Food and Drugs. Part 600, Biological Products: General. Section 600.3. 2010.
  • 35.Hendriksen C.F.M. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Exp. Rev. Vaccines. 2009;8:313–322. doi: 10.1586/14760584.8.3.313. [DOI] [PubMed] [Google Scholar]
  • 36.Coombes L., Stickings P., Tierney R., Rigsby P., Sesardic D. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. J Immunol Methods. 2009;350:142–149. doi: 10.1016/j.jim.2009.09.002. [DOI] [PubMed] [Google Scholar]
  • 37.European Pharmacopoeia. Monograph 20708. Assay of tetanus vaccine (adsorbed), Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 38.United States Minimum Requirements: Tetanus toxoid, 1952.
  • 39.World Health Organization. Annex 5. Recommendations for diphtheria, tetanus, pertussis and combined vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva, World Health Organization, 2005,.(WHO Technical Report Series No. 927). [PubMed]
  • 40.European Pharmacopoeia. Monograph 20706. Assay of diphtheria vaccine (adsorbed), Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.Ph Eur 2.7.6.
  • 41.United States Minimum Requirements: Diphtheria, 1947.
  • 42.European Pharmacopoeia. Monograph 1356. Pertussis Vaccine Acellular Component, Absorbed, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 43.European Pharmacopoeia. Monograph 1595. Pertussis Vaccine Acellular, Copurified, Absorbed, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 44.Japanese Minimum Requirements for Biological Products. National Institute of Infectious Diseases, Japan 2006.
  • 45.World Health Organization. Annex 2. Guidelines for the production and control of the acelluar pertussis compenent of monovalent or combined vaccines. In: WHO Expert Committee on Biological Standardization. Forty-seventh report. Geneva, World Health Organization, 1998, (WHO Technical Report Series No. 878).
  • 46.European Pharmacopoeia. Monograph 0216. Rabis vaccine for human use prepared in cell cultures, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 47.World Health Organization. Annex 2. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. In: WHO Expert Committee on Biological Standardization. Fifty-sixth report. Geneva, World Health Organization, 2007,.(WHO Technical Report Series No. 941).
  • 48.Seligmann EB. The NIH test for potency. In: Laboratory techniques in rabies (Eds Kaplan MM and Koprowski H) 3rd edn. WHO, Geneva, 1973:279-286. [PubMed]
  • 49.Descamps J, Mary A, Rommel E, Anhoury ML, De Neys R, Duchêne M. Release potency tests of hepatitis vaccines. In: Sesardic D, Brown F, Hendriksen CFM, editors. Alternatives to Animals in the Development and Control of Biological Products for Human and Veterinary Use. Meeting of the International Association of Biological Standardization. September 1998. London. Dev Biol Stand (Basel): Karger, 1999;100:289-94.
  • 50.Landys Shovel Cuervo M., Reyes H.N. Validation of an in vitro potency test for the Cuban hepatitis B vaccine. Dev Biol. 2002;111:305–312. [PubMed] [Google Scholar]
  • 51.European Pharmacopoeia. Monograph 1935. Hepatitis A Vaccine Inactivated, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 52.European Pharmacopoeia. Monograph 20701. Immunochemical methods, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 53.World Health Organization. Requirements for Hepatitis A Vaccine Inactivated. In: WHO Expert Committee on Biological Standardization. Forty-fifth report. Geneva, World Health Organization, 1995,.(WHO Technical Report Series No. 858). [PubMed]
  • 54.European Pharmacopoeia. Monograph 1056. Hepatitis B Vaccine rDNA, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 55.Method of Analysis. Biological assays: Assay of hepatitis B vaccine (rDNA) [ch. 2.7.15]. In: European Pharmacopoeia, 67th ed. Strasbourg, France: European Department for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 2011.
  • 56.World Health Organization. Requirements for Hepatitis B Vaccine Inactivated. In: WHO Expert Committee on Biological Standardization. Forty-eighth report. Geneva, World Health Organization, 1999,.(WHO Technical Report Series No. 889).
  • 57.European Pharmacopoeia. Monograph 214. Poliomyelitis Vaccine Inactivated, Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 58.World Health Organization. Requirements for Oral Poliomyelitis Vaccine. In: WHO Expert Committee on Biological Standardization. Fifty-first report. Geneva, World Health Organization, 2002,.(WHO Technical Report Series No. 910). [PubMed]
  • 59.Bruckner L., Cussler K., Halder M., Barrat J., Castle P., Duchow K., Gatewood D.M., Gibert R., Groen J., Knapp B., Levis R., Milne C., Parker S., Stünkel K., Visser N., Volkers P. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM Workshop 48. ALTA. 2003;31:429–454. doi: 10.1177/026119290303100409. [DOI] [PubMed] [Google Scholar]
  • 60.Gamoh K., Senda M., Itoh O., Muramatsu M., Hirayama N., Koike R., Endoh Y.S., Minamoto N. Use of ELISA for in vitro potency test of rabies vaccine for animals use. Biologicals. 1996;24:95–101. doi: 10.1006/biol.1996.0012. [DOI] [PubMed] [Google Scholar]
  • 61.Rooijakkers E.J., Uittenboogaard J.P., Groen J., Osterhaus A.D. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J Virol Methods. 1996;58:111–119. doi: 10.1016/0166-0934(95)01999-5. [DOI] [PubMed] [Google Scholar]
  • 62.European Pharmacopoeia. Monograph XXXX: 0451 – Rabies vaccine (inactivated) for veterinary use. Pharmeuropa 2011;13:128-131.
  • 63.Prieur S., Broc S., Gal M., Poirer B., Fuchs F. Development of an in vitro potency test for tetanus vaccines: an immunoassay based on Hc fragment determination. Dev Biol. 2002;111:37–46. [PubMed] [Google Scholar]
  • 64.Redhead K., Sesardic D., Yost S.E., Attwell A.M., Watkins J., Hoy C.S., Plumb J.E., Corbel M.J. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity. Biologicals. 1994;22(4):339–345. doi: 10.1006/biol.1994.1052. [DOI] [PubMed] [Google Scholar]
  • 65.Shams H., Heron I. Mutual interactions between DTaP-IPV and Haemophilus influenzae type b (Hib)-conjugated vaccines in laboratory animal models. Biologicals. 1999;27(3):227–240. doi: 10.1006/biol.1999.0180. [DOI] [PubMed] [Google Scholar]
  • 66.Gerdts V., van Drunen Little-van den Hurk S., Griebel P.J., Babiuk L.A. Use of animals models in the development of human vaccines. Future Microbiol. 2007;2(6):667–675. doi: 10.2217/17460913.2.6.667. [DOI] [PubMed] [Google Scholar]
  • 67.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.65. SAM 600: Supplemental Assay Method for Purity, Potency and Dissociation of Brucella abortus Vaccine, Strain l9. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 68.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.67. SAM 612: Supplemental Assay Method for Bacterial Plate Count of Erysipelothrix rhusiopathiae Vaccines. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 69.Section 113.68. SAM 905: Supplemental Assay Method for Test for Potency of Live Avirulent Pasteurella haemolytica Vaccine. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_900_series.shtml.
  • 70.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.71. SAM 319: Supplemental Assay Method for Titration of Chlamydophila felis (formerly Feline Chlamydia psittaci) in Embryonated Chicken Eggs. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 71.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.314. SAM 306: Supplemental Assay Method for the Titration of Feline Calicivirus in Cell Culture. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 72.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.315. SAM 307: Supplemental Assay Method for the Titration of Feline Rhinotracheitis Virus in Cell Culture. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 73.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.330. SAM 406: Supplemental Assay Method for Titration of Monovalent, Cell Associated Marek's Disease Vaccines of Serotypes 1, 2 or 3. 2005. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_400_series.shtml.
  • 74.European Pharmacopoeia. Monograph 01/2008:0589. Marek's disease vaccine (live). 7th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2010.
  • 75.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 114: Supplemental Assay Method for Titration of Porcine Transmissible Gastroenteritis Virus. 2011. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_100_series.shtml.
  • 76.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 121: Supplemental Assay Method for Titration of Porcine Rotovirus In Modified-Live Vaccines. 2005. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_100_series.shtml.
  • 77.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.305. SAM 304: Supplemental Assay Method for Titration of Infectious Canine Hepatitis Virus in Primary Canine Kidney Cell Culture. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 78.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.306. SAM 323: Supplemental Assay Method for Titration of Canine Distemper Virus in Vero Cell Culture. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 79.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.331. SAM 408: Supplemental Assay Method for Titrating Tissue Culture Adapted Vaccine Strains of Infectious Bursal Disease Virus. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_400_series.shtml.
  • 80.European Pharmacopoeia. Monograph 01/2008:0587. Avian infectious bursal disease vaccine (live). 7th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2010.
  • 81.Thornton D.H. Standard requirements for vaccines against infectious bursal disease. Dev Biol Stand. 1976;33:343–348. [PubMed] [Google Scholar]
  • 82.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.304. SAM 305: Supplemental Assay Method for Titration of Feline Panleukopenia Virus in Cell Culture. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 83.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.317. SAM 316. Supplemental Assay Method for the Titration of Canine Parvovirus in Cell Culture. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 84.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.302. SAM 303: Supplemental Assay Method for the Titration of Distemper Virus in Embryonated Chicken Eggs. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 85.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.119. SAM 613: Supplemental Assay Method for In vitro Potency Testing of Erysipelothrix rhusiopathiae Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 86.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.119. SAM 611: Supplemental Assay Method for Potency Testing of Erysipelas Bacterins in Mice. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 87.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 620-623: Supplemental Assay Method for Potency Testing Enterotoxigenic (K99, K 88, 987P, F41 Pilus) Escherichia coli Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 88.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.101. SAM 624: Supplemental Assay Method for in vitro Potency testing of Leptospira interrogans Serovar pomona Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 89.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.101. SAM 608: Supplemental Assay Method for Potency Assay of Leptospira interrogans Serovar pomona Bacterins. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 90.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.103. SAM 625: Supplemental Assay Method for in vitro Potency testing of Leptospira interrogans Serovar canicola Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 91.European Pharmacopoeia. Monograph 01/2008:0447. Canine Leptospirosis Vaccine (Inactivated). 5th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 92.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.103. SAM 609: Supplemental Assay Method for Potency Assay of Leptospira interrogans Serovar canicola Bacterins. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 93.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.104. SAM 626: Supplemental Assay Method for in vitro Potency testing of Leptospira interrogans Serovar grippotyphosa Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 94.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.104. SAM 617: Supplemental Assay Method for Potency Assay of Leptospira interrogans Serovar grippotyphosa Bacterins. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 95.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.102. SAM 627: Supplemental Assay Method for in vitro Potency testing of Leptospira interrogans Serovar icterohaemorrhagiae Bacterins. 2009. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 96.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.102. SAM 610: Supplemental Assay Method for Potency Assay of Leptospira interrogans Serovar icterohaemorrhagiae Bacterins. 2008. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_600_series.shtml.
  • 97.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. Section 113.105. Leptospira hardjo bacterin. 2002.
  • 98.European Pharmacopoeia. Monograph 01/2008:1939. Bovine Leptospirosis Vaccine (Inactivated). 5th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 99.Hendriksen C., Replacement reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev Vaccines. 2008;8(3):313–322. doi: 10.1586/14760584.8.3.313. [DOI] [PubMed] [Google Scholar]
  • 100.United States Department of Agriculture, Center for Veterinary Biologics, Veterinary Services Memorandum No. 800.104. In vitro serial release potency test for completed product containing Clostridium chauvoei. 2003.
  • 101.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 220. Not available.
  • 102.European Pharmacopoeia. Monograph 01/2008:0361. Clostridium chauvoei vaccine for veterinary use. 6th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 103.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 120: Supplemental Assay Method for the in vitro Potency Assay of Bovine Respiratory Viruses in Killed Vaccines. 1991. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_100_series.shtml.
  • 104.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 321: Supplemental Assay Method for Quantitating the GP70 Antigen of Feline Leukemia Virus Veterinary Vaccines. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 105.Shibley G.P., Tanner J.E., Hanna S.A. United States Department of Agriculture licensing requirements for feline leukemia virus vaccines. JAVMA. 1991;199:1402–1406. [PubMed] [Google Scholar]
  • 106.United States Department of Agriculture, Center for Veterinary Biologics, Code of Federal Regulations, Title 9, Animals and Animal Products. Part 113- Standard Requirements. SAM 322: Supplemental Assay Method for Determination of the Specific Viral Antigen Content in Inactivated Canine Coronavirus Vaccines. 2007. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_sams_300_series.shtml.
  • 107.European Pharmacopoeia. Monograph 01/2008:0870. Newcastle Disease Vaccine (Inactivated). 5th ed. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
  • 108.Hendriksen C. Three Rs achievements in vaccinology. AATEX Special Issue. 2007;14:575–579. [Google Scholar]
  • 109.Claassen I., Maas R., Oei H., Daas A., Milne C. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of Newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation. Pharmeuropa Bio. 2004;1:1–15. [PubMed] [Google Scholar]
  • 110.EDQM International Symposium on Alternatives to animal testing new approaches in the development and control of biologicals, Dubrovnik, Croatia, 23-24 April 2008.
  • 111.Symposium, Practical Alternatives to Reduce Animal Testing in Quality Control of Veterinary Biologicals in the Americas, Buenos Aires, Argentina, February, 2010.
  • 112.De Mattia F., Chapsal J.-M., Descamps J., Halder M., Jarrett N., Kross I., Mortiaux F., Ponsar C., Redhead K., McKelvie J., Hendriksen C. The consistency approach for quality control of vaccines – a strategy to improve quality control and implement 3Rs. Biologicals. 2011;39:59–65. doi: 10.1016/j.biologicals.2010.12.001. [DOI] [PubMed] [Google Scholar]

Articles from Procedia in Vaccinology are provided here courtesy of Elsevier

RESOURCES